- Pfizer Inc PFE has initiated a Phase 3 clinical trial evaluating its respiratory syncytial virus (RSV) bivalent prefusion F subunit investigational vaccine candidate (RSVpreF) in adults ages 60 years or older.
- The Phase 3 RENOIR trial will enroll approximately 30,000 participants 60 years and older.
- The study's primary objectives will assess safety and efficacy for preventing moderate to severe lower respiratory tract illness (msLRTI-RSV) during the first RSV season.
- Related Content: Moderna RSV-Targeted mRNA Vaccine Candidate Gets Fast Track Tag In US
- Price Action: PFE stock is up 0.53% at $46.29 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
